Kanagawa, Japan, 28, May 2020 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Mikio Kawahara, M.B.A., Chief Investment Officer of UTokyo Innovation Platform Co., Ltd, and Yusuke Miyazaki, Ph.D., Investment Manager of ANRI have been appointed as new Board of Directors.
Former Chief Financial Officer, Yusuke Kohno has decided to pursue new journey as an entrepreneur.
“Yusuke Kohno’s contributions have positioned the company on a successful trajectory.” said Yusuke Tominari, Ph.D., CEO and CSO of FIMECS “We are excited to welcome Mikio Kawahara and Yusuke Miyazaki to FIMECS, look forward to working with new Board of Directors to accelerate the research in the targeted protein degradation field, and will contribute to deliver life-saving medicines to patients around the world.”
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-32-1169
Email: info@fimecs.com